Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial - 30/07/24
, Cyrille Hulin, MD b, Aurore Perrot, MD c, Bertrand Arnulf, MD e, Karim Belhadj, MD f, Lotfi Benboubker, MD g, Sonja Zweegman, ProfMD h, Hélène Caillon, PharmD i, Denis Caillot, MD k, Hervé Avet-Loiseau, ProfMD d, Michel Delforge, ProfMD l, Thomas Dejoie, PharmD i, Thierry Facon, ProfMD m, Cécile Sonntag, MD n, Jean Fontan, MD o, Mohamad Mohty, MD p, Kon-Siong Jie, MD q, Lionel Karlin, MD r, Frédérique Kuhnowski, MD s, Jérôme Lambert, MD t, Xavier Leleu, ProfMD u, Margaret Macro, MD v, Frédérique Orsini-Piocelle, MD w, Murielle Roussel, MD x, Jean Marc Schiano de Colella, MD y, Niels WCJ van de Donk, ProfMD h, Soraya Wuillème, PharmD j, Annemiek Broijl, MD z, Cyrille Touzeau, MD a, Mourad Tiab, MD aa, Jean-Pierre Marolleau, ProfMD ab, Nathalie Meuleman, ProfMD ac, Marie-Christiane Vekemans, MD ad, Matthijs Westerman, MD ae, Saskia K Klein, MD af, Mark-David Levin, MD ag, Fritz Offner, ProfMD ah, Martine Escoffre-Barbe, MD ai, Jean-Richard Eveillard, MD aj, Réda Garidi, MD ak, Winnie Hua, MA al, Jianping Wang, PhD am, Alba Tuozzo, MS am, Carla de Boer, PhD an, Melissa Rowe, MD ao, Veronique Vanquickelberghe, PhD ap, Robin Carson, MD am, Jessica Vermeulen, MD an, Jill Corre, MD d, Pieter Sonneveld, ProfMD zon behalf of the
Intergroupe Francophone du Myélome, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology and the CASSIOPEIA Investigators
Summary |
Background |
CASSIOPEIA part 1 demonstrated superior depth of response and prolonged progression-free survival with daratumumab in combination with bortezomib, thalidomide, and dexamethasone (D-VTd) versus bortezomib, thalidomide, and dexamethasone (VTd) alone as an induction and consolidation regimen in transplant-eligible patients newly diagnosed with myeloma. In CASSIOPEIA part 2, daratumumab maintenance significantly improved progression-free survival and increased minimal residual disease (MRD)-negativity rates versus observation. Here, we report long-term study outcomes of CASSIOPEIA.
Methods |
CASSIOPEIA was a two-part, open-label, phase 3 trial of patients done at 111 European academic and community-based centres. Eligible patients were aged 18–65 years with transplant-eligible newly diagnosed myeloma and an Eastern Cooperative Oncology Group performance status of 0–2. In part 1, patients were randomly assigned (1:1) to pre-transplant induction and post-transplant consolidation with D-VTd or VTd. Patients who completed consolidation and had a partial response or better were re-randomised (1:1) to intravenous daratumumab maintenance (16 mg/kg every 8 weeks) or observation for 2 years or less. An interactive web-based system was used for both randomisations, and randomisation was balanced using permuted blocks of four. Stratification factors for the first randomisation (induction and consolidation phase) were site affiliation, International Staging System disease stage, and cytogenetic risk status. Stratification factors for the second randomisation (maintenance phase) were induction treatment and depth of response in the induction and consolidation phase. The primary endpoint for the induction and consolidation phase was the proportion of patients who achieved a stringent complete response after consolidation; results for this endpoint remain unchanged from those reported previously. The primary endpoint for the maintenance phase was progression-free survival from second randomisation. Efficacy evaluations in the induction and consolidation phase were done on the intention-to-treat population, which included all patients who underwent first randomisation, and efficacy analyses in the maintenance phase were done in the maintenance-specific intention-to-treat population, which included all patients who were randomly assigned at the second randomisation. This analysis represents the final data cutoff at the end of the study. The trial is registered with ClinicalTrials.gov, NCT02541383.
Findings |
Between Sept 22, 2015 and Aug 1, 2017, 1085 patients were randomly assigned to D-VTd (n=543) or VTd (n=542); between May 30, 2016 and June 18, 2018, 886 were re-randomised to daratumumab maintenance (n=442) or observation (n=444). At the clinical cutoff date, Sept 1, 2023, median follow-up was 80·1 months (IQR 75·7–85·6) from first randomisation and 70·6 months (66·4–76·1) from second randomisation. Progression-free survival from second randomisation was significantly longer in the daratumumab maintenance group than the observation-alone group (median not reached [95% CI 79·9–not estimable (NE)] vs 45·8 months [41·8–49·6]; HR 0·49 [95% CI 0·40–0·59]; p<0·0001); benefit was observed with D-VTd with daratumumab maintenance versus D-VTd with observation (median not reached [74·6–NE] vs 72·1 months [52·8–NE]; 0·76 [0·58–1·00]; p=0·048) and VTd with daratumumab maintenance versus VTd with observation (median not reached [66·9–NE] vs 32·7 months [27·2–38·7]; 0·34 [0·26–0·44]; p<0·0001).
Interpretation |
The long-term follow-up results of CASSIOPEIA show that including daratumumab in both the induction and consolidation phase and the maintenance phase led to superior progression-free survival outcomes. Our results confirm D-VTd induction and consolidation as a standard of care, and support the option of subsequent daratumumab monotherapy maintenance, for transplant-eligible patients with newly diagnosed multiple myeloma.
Funding |
Intergroupe Francophone du Myélome, Dutch-Belgian Cooperative Trial Group for Hematology Oncology, and Janssen Research & Development.
Le texte complet de cet article est disponible en PDF.Plan
Vol 25 - N° 8
P. 1003-1014 - août 2024 Retour au numéro
Article précédent
- Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
- Yi-Long Wu, Valentina Guarneri, Pei Jye Voon, Boon Khaw Lim, Jin-Ji Yang, Marie Wislez, Cheng Huang, Chong Kin Liam, Julien Mazieres, Lye Mun Tho, Hidetoshi Hayashi, Nguyen Viet Nhung, Puey Ling Chia, Filippo de Marinis, Jo Raskin, Qinghua Zhou, Giovanna Finocchiaro, Anh Tuan Le, Jialei Wang, Christophe Dooms, Terufumi Kato, Ernest Nadal, How Soon Hin, Egbert F Smit, Martin Wermke, Daniel Tan, Masahiro Morise, Aurora O’Brate, Svenja Adrian, Boris M Pfeiffer, Christopher Stroh, Dilafruz Juraeva, Rainer Strotmann, Kosalaram Goteti, Karin Berghoff, Barbara Ellers-Lenz, Niki Karachaliou, Xiuning Le, Tae Min Kim, INSIGHT 2 investigators
- Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial
- Salomon Tendler, Mark P Dunphy, Matthew Agee, Joseph O’Donoghue, Rania G Aly, Noura J Choudhury, Adam Kesner, Assen Kirov, Audrey Mauguen, Marina K Baine, Heiko Schoder, Wolfgang A Weber, Natasha Rekhtman, Serge K Lyashchenko, Lisa Bodei, Michael J Morris, Jason S Lewis, Charles M Rudin, John T Poirier
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?